Should a pregnant woman with diabetes who is taking metformin switch to insulin therapy?

Should Pregnant Women with Diabetes on Metformin Switch to Insulin?

Yes, pregnant women with preexisting type 2 diabetes taking metformin should switch to insulin therapy, as insulin is the preferred treatment for type 2 diabetes in pregnancy. For gestational diabetes mellitus (GDM), metformin may be continued as an alternative to insulin, though insulin remains preferred. 1, 2

Type 2 Diabetes in Pregnancy: Switch to Insulin

For women with preexisting type 2 diabetes, insulin is strongly preferred over metformin. The 2025 Endocrine Society/European Society of Endocrinology guidelines explicitly recommend against routinely adding metformin to insulin in pregnant individuals with type 2 diabetes already on insulin (Grade 2, very low quality evidence). 2 The rationale is clear: women with type 2 diabetes have more severe insulin deficiency and insulin resistance than those with GDM, making metformin insufficient as monotherapy. 2

Key Concerns with Metformin in Type 2 Diabetes Pregnancy:

• Placental transfer: Metformin readily crosses the placenta, achieving fetal levels equal to or higher than maternal levels due to high OCT3 transporter expression in second and third trimesters 1, 2
• Fetal effects: Metformin concentrates 1000-fold in fetal and placental mitochondria, inhibiting mitochondrial complex 1 respiration 2
• Growth restriction risk: Studies in primates show decreased fetal weight and skeletal muscle mass with maternal metformin exposure 2
• Long-term offspring concerns: Multiple follow-up studies demonstrate increased childhood BMI, waist circumference, and obesity risk in offspring exposed to metformin in utero 1, 2

The FDA label states that "limited data with metformin in pregnant women are not sufficient to determine a drug-associated risk" and notes that "the developmental and health benefits should be considered along with the mother's clinical need." 3 This cautious language supports switching to the better-studied insulin.

Gestational Diabetes Mellitus: Metformin as Alternative

For GDM specifically, metformin may be used as an alternative to insulin, though insulin remains the preferred first-line agent. 1 The 2025 ADA Standards of Care state that "insulin is preferred for the management of GDM" but acknowledge metformin's role. 1

When Metformin May Be Acceptable in GDM:

• Lower cost and oral administration make it more acceptable to patients 2
• Reduces neonatal hypoglycemia risk compared to insulin 1, 4
• Decreases maternal weight gain 1, 5
• Lower rates of cesarean delivery in some studies 5
• However, 14-46% of women on metformin monotherapy require supplemental insulin 1, 4

Predictors of Metformin Failure Requiring Insulin:

• Older maternal age 6
• Obesity (BMI >30) 7
• Higher screening glucose tolerance test values 6
• Fasting glucose ≥90 mg/dL at diagnosis 7
• Multiparity 7

Critical Caveats About Metformin in GDM:

The long-term offspring data remain concerning even in GDM populations. The MiG TOFU study showed 9-year-old children exposed to metformin had higher BMI, waist-to-height ratios, and waist circumferences compared to insulin-exposed children (Auckland cohort). 1 A meta-analysis confirmed metformin exposure results in smaller neonates with accelerated postnatal growth and higher childhood BMI. 1

Practical Algorithm for Decision-Making

For Type 2 Diabetes:

1. Switch from metformin to insulin at pregnancy confirmation or preconception
2. Use basal-bolus insulin regimen with frequent glucose monitoring 1
3. Consider automated insulin delivery (AID) systems if available 1

For GDM:

1. First-line: Insulin therapy when lifestyle modifications fail
2. Alternative: Metformin if:
   • Patient strongly prefers oral medication
   • Cost is prohibitive barrier to insulin
   • Patient has good adherence and glucose monitoring capability
3. Counsel patients about:
   • 14-46% chance of needing supplemental insulin 1
   • Potential long-term effects on offspring weight/metabolism 1, 2
   • Need for close monitoring
4. Add insulin promptly if:
   • Glucose targets not met within 1-2 weeks
   • Fasting glucose remains ≥90 mg/dL
   • Patient is obese or has other risk factors for metformin failure

Insulin Remains Gold Standard

Insulin does not cross the placenta, has decades of safety data in pregnancy, and can be precisely titrated to achieve tight glycemic control. 1 Modern basal-bolus regimens with rapid-acting analogs minimize hypoglycemia while optimizing glucose control. 8 The physiologic approach mimics endogenous insulin secretion patterns and allows flexibility in meal timing and content.

The evidence strongly supports insulin as preferred therapy for type 2 diabetes in pregnancy, with metformin reserved as an alternative option primarily for GDM when insulin is not feasible.